Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Nanoemulsion-Based Delivery of Fluorescent PARP Inhibitors in Mouse Models of Small Cell Lung Cancer.

Gonzales J, Kossatz S, Roberts S, Pirovano G, Brand C, Pérez-Medina C, Donabedian P, de la Cruz MJ, Mulder WJM, Reiner T.

Bioconjug Chem. 2018 Nov 21;29(11):3776-3782. doi: 10.1021/acs.bioconjchem.8b00640. Epub 2018 Nov 7.

2.

PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer.

Lok BH, Gardner EE, Schneeberger VE, Ni A, Desmeules P, Rekhtman N, de Stanchina E, Teicher BA, Riaz N, Powell SN, Poirier JT, Rudin CM.

Clin Cancer Res. 2017 Jan 15;23(2):523-535. doi: 10.1158/1078-0432.CCR-16-1040. Epub 2016 Jul 20.

3.

Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.

Yuan B, Ye N, Song SS, Wang YT, Song Z, Chen HD, Chen CH, Huan XJ, Wang YQ, Su Y, Shen YY, Sun YM, Yang XY, Chen Y, Guo SY, Gan Y, Gao ZW, Chen XY, Ding J, He JX, Zhang A, Miao ZH.

Cancer Lett. 2017 Feb 1;386:47-56. doi: 10.1016/j.canlet.2016.11.010. Epub 2016 Nov 12.

PMID:
27847302
4.

In vitro analysis of PARP inhibitor nanoformulations.

Baldwin P, Tangutoori S, Sridhar S.

Int J Nanomedicine. 2018 Mar 15;13(T-NANO 2014 Abstracts):59-61. doi: 10.2147/IJN.S124992. eCollection 2018.

5.

CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or Olaparib.

Sen T, Tong P, Stewart CA, Cristea S, Valliani A, Shames DS, Redwood AB, Fan YH, Li L, Glisson BS, Minna JD, Sage J, Gibbons DL, Piwnica-Worms H, Heymach JV, Wang J, Byers LA.

Cancer Res. 2017 Jul 15;77(14):3870-3884. doi: 10.1158/0008-5472.CAN-16-3409. Epub 2017 May 10.

6.

[Effect and Mechanism of Radiosensitization of Poly (ADP-Ribose) Polymerase Inhibitor n Lewis Cells and Xenografts].

Wang W, Duan B, Zeng L.

Zhongguo Fei Ai Za Zhi. 2016 Jan;19(1):16-23. doi: 10.3779/j.issn.1009-3419.2016.01.02. Chinese.

7.

Activation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung Cancer.

Cardnell RJ, Feng Y, Mukherjee S, Diao L, Tong P, Stewart CA, Masrorpour F, Fan Y, Nilsson M, Shen Y, Heymach JV, Wang J, Byers LA.

PLoS One. 2016 Apr 7;11(4):e0152584. doi: 10.1371/journal.pone.0152584. eCollection 2016.

8.

PARP1-siRNA suppresses human prostate cancer cell growth and progression.

Lai Y, Kong Z, Zeng T, Xu S, Duan X, Li S, Cai C, Zhao Z, Wu W.

Oncol Rep. 2018 Apr;39(4):1901-1909. doi: 10.3892/or.2018.6238. Epub 2018 Jan 26.

PMID:
29393407
9.

Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer.

Ivy SP, Liu JF, Lee JM, Matulonis UA, Kohn EC.

Expert Opin Investig Drugs. 2016;25(5):597-611. doi: 10.1517/13543784.2016.1156857. Epub 2016 Mar 16. Review.

PMID:
26899229
10.

Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer.

Cardnell RJ, Feng Y, Diao L, Fan YH, Masrorpour F, Wang J, Shen Y, Mills GB, Minna JD, Heymach JV, Byers LA.

Clin Cancer Res. 2013 Nov 15;19(22):6322-8. doi: 10.1158/1078-0432.CCR-13-1975. Epub 2013 Sep 27.

11.

New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.

Liu FW, Tewari KS.

Curr Treat Options Oncol. 2016 Mar;17(3):12. doi: 10.1007/s11864-015-0378-9. Review.

12.

PARPi-FL--a fluorescent PARP1 inhibitor for glioblastoma imaging.

Irwin CP, Portorreal Y, Brand C, Zhang Y, Desai P, Salinas B, Weber WA, Reiner T.

Neoplasia. 2014 May;16(5):432-40. doi: 10.1016/j.neo.2014.05.005. Epub 2014 Jun 23.

13.

Olaparib: an oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian cancer.

Gunderson CC, Moore KN.

Future Oncol. 2015;11(5):747-57. doi: 10.2217/fon.14.313. Review.

PMID:
25757679
14.

Target engagement imaging of PARP inhibitors in small-cell lung cancer.

Carney B, Kossatz S, Lok BH, Schneeberger V, Gangangari KK, Pillarsetty NVK, Weber WA, Rudin CM, Poirier JT, Reiner T.

Nat Commun. 2018 Jan 12;9(1):176. doi: 10.1038/s41467-017-02096-w.

15.

Olaparib for the treatment of ovarian cancer.

Bornstein E, Jimeno A.

Drugs Today (Barc). 2016 Jan;52(1):17-28. doi: 10.1358/dot.2016.52.1.2440714. Review.

PMID:
26937492
16.

A high-throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer.

Postel-Vinay S, Bajrami I, Friboulet L, Elliott R, Fontebasso Y, Dorvault N, Olaussen KA, André F, Soria JC, Lord CJ, Ashworth A.

Oncogene. 2013 Nov 21;32(47):5377-87. doi: 10.1038/onc.2013.311. Epub 2013 Aug 12.

PMID:
23934192
17.

Poly (ADP) ribose polymerase inhibition: A potential treatment of malignant peripheral nerve sheath tumor.

Kivlin CM, Watson KL, Al Sannaa GA, Belousov R, Ingram DR, Huang KL, May CD, Bolshakov S, Landers SM, Kalam AA, Slopis JM, McCutcheon IE, Pollock RE, Lev D, Lazar AJ, Torres KE.

Cancer Biol Ther. 2016;17(2):129-38. doi: 10.1080/15384047.2015.1108486. Epub 2015 Dec 9.

18.

Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.

Rafii S, Gourley C, Kumar R, Geuna E, Ern Ang J, Rye T, Chen LM, Shapira-Frommer R, Friedlander M, Matulonis U, De Greve J, Oza AM, Banerjee S, Molife LR, Gore ME, Kaye SB, Yap TA.

Oncotarget. 2017 Jul 18;8(29):47154-47160. doi: 10.18632/oncotarget.17005.

19.

Synthesis and Evaluation of a Radioiodinated Tracer with Specificity for Poly(ADP-ribose) Polymerase-1 (PARP-1) in Vivo.

Zmuda F, Malviya G, Blair A, Boyd M, Chalmers AJ, Sutherland A, Pimlott SL.

J Med Chem. 2015 Nov 12;58(21):8683-93. doi: 10.1021/acs.jmedchem.5b01324. Epub 2015 Oct 27.

20.

What Is the Place of PARP Inhibitors in Ovarian Cancer Treatment?

Liu JF, Matulonis UA.

Curr Oncol Rep. 2016 May;18(5):29. doi: 10.1007/s11912-016-0515-z. Review.

PMID:
26984416

Supplemental Content

Support Center